The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...